Harmony Biosciences Holdings Inc [HRMY] stock prices are up 3.26% to $39.08 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HRMY shares have gain 0.76% over the last week, with a monthly amount glided 7.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Harmony Biosciences Holdings Inc [NASDAQ: HRMY] stock has seen the most recent analyst activity on February 11, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $55. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 17, 2024, and set its price target to $75. UBS started tracking the stock assigning a Buy rating and suggested a price target of $56 on September 10, 2024. Citigroup initiated its recommendation with a Buy and recommended $48 as its price target on June 21, 2024. BofA Securities downgraded its rating to Underperform for this stock on January 02, 2024, but kept the price target unchanged to $30. In a note dated September 25, 2023, Goldman downgraded an Sell rating on this stock and revised its target price from $40 to $31.
The stock price of Harmony Biosciences Holdings Inc [HRMY] has been fluctuating between $28.14 and $41.61 over the past year. Currently, Wall Street analysts expect the stock to reach $45.33 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $39.08 at the most recent close of the market. An investor can expect a potential return of 15.99% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
The Harmony Biosciences Holdings Inc [NASDAQ:HRMY] reported sales of 681.88M for trailing twelve months, representing a surge of 16.08%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.23 and Total Capital is 0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.05 points at the first support level, and at 37.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 40.00, and for the 2nd resistance point, it is at 40.93.
Ratios To Look Out For
It’s worth pointing out that Harmony Biosciences Holdings Inc [NASDAQ:HRMY]’s Current Ratio is 3.24. Also, the Quick Ratio is 3.20, while the Cash Ratio stands at 2.4. Considering the valuation of this stock, the price to sales ratio is 3.27, the price to book ratio is 3.73 and price to earnings (TTM) ratio is 18.50.
Transactions by insiders
Recent insider trading involved Dierks Jeffrey, CHIEF COMMERCIAL OFFICER, that happened on Jan 24 ’25 when 13125.0 shares were sold. CHIEF COMMERCIAL OFFICER, Dierks Jeffrey completed a deal on Jan 27 ’25 to sell 1629.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Kapadia Sandip sold 1775.0 shares on Jan 27 ’25.
